Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A Phase III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a World Health Organization (WHO) -recommended regimen for preventing confirmed or probable tuberculosis disease (TBD) during 96 weeks of follow-up among people living with HIV (PLHIV) and high-risk Close Contacts (CC) of adults with Drug Susceptible (DS) or Rifampin Resistant (RR) TB.
Epistemonikos ID: 385b714df20f1756ac037366a71cd0d5a5cd28dc
First added on: Sep 01, 2024